Veru Inc

NASDAQ:VERU   12:55:23 PM EDT
12.81
+0.44 (+3.56%)
Earnings Announcements

Veru Reports Second Quarter Fiscal 2022 Results And Progress Of Sabizabulin For Covid-19 Toward A Request For Emergency Use Authorization

Published: 05/12/2022 10:38 GMT
Veru Inc (VERU) - Veru Reports Second Quarter Fiscal 2022 Results and Progress of Sabizabulin for Covid-19 Toward a Request for Emergency Use Authorization.
Q2 Loss per Share $0.18.
Q2 Revenue Fell 3 Percent to $27.2 Million.
Eua Application Submission for Sabizabulin Covid-19 Treatment Expected by Calendar Q2 2022.
Revenue is expected to be $16.67 Million
Adjusted EPS is expected to be -$0.16

Next Quarter Revenue Guidance is expected to be $19.06 Million
Next Quarter EPS Guidance is expected to be -$0.16

More details on our Analysts Page.